Cardiology Department Policy in Japan After Coronavirus Disease-2019 (COVID-19) — Descriptive Summary of 2nd Nationwide Survey by the Japanese Circulation Society —

Atsushi Mizuno, MD, PhD; Chisa Matsumoto, MD, PhD; Takuya Kishi, MD, PhD; Mari Ishida, MD, PhD; Shoji Sanada, MD, PhD; Memori Fukuda, MD; Issei Komuro, MD, PhD; Kenichi Hirata, MD, PhD; Koichi Node, MD, PhD

Background: Cardiovascular department restriction policies on procedures resulting from the COVID-19 pandemic have not been fully evaluated.

Methods and Results: We performed a retrospective analysis of a nationwide survey performed by the Japanese Circulation Society in August 2020. The total response rate was 48.9% (651/1,331). The rate of restriction of cardiovascular procedures peaked in April. Exacerbations of heart failure due to hospital restrictions were noted in 43.8% of departments.

Conclusions: Many departments restricted their cardiological procedures, and this rate changed according to the pandemic situation. The exacerbation of cardiovascular disease resulting from pandemic restrictions should not be ignored.

Key Words: Medical policy; Pandemics

Since the end of 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated coronavirus disease-2019 (COVID-19) have spread throughout the world. Due to the virus’s highly infectious nature and hospitals lacking sufficient medical resources, many cardiovascular procedures and hospitalizations have been restricted and non-urgent procedures have been rescheduled and postponed. In cardiology, many associations and groups, such as the American College of Cardiology and the European Society of Cardiology, have offered recommendations on what to do about non-urgent procedures and outpatient clinic visits. Despite many statements about the restrictions, the actual departmental policies during the COVID-19 pandemic, especially in Japan, have not been fully evaluated. The Japanese Circulation Society (JCS) performed a nationwide survey of cardiology departmental policy to guide institutional decision making. In light of the current increasing number of COVID-19, an analysis of departmental decisions from early in 2020 would be useful to many decision makers. Thus, the chief objective of this study was to explore cardiology departments’ policy changes in early 2020 in Japan.

Methods

Study Population

This was a retrospective analysis of the 2nd nationwide...
Questionnaire
This 2nd survey asked each institution about: (1) general hospital and department policies about COVID-19 patients; (2) specific policies on the restriction of examinations and procedures in the cardiology department for all patients, especially including non-COVID-19 patients; and (3) experiences related to the exacerbation of non-COVID-19 typical cardiovascular diseases (ischemic heart disease, aortic/peripheral artery disease, heart failure, arrhythmia, and hypertension) due to restraints by the patients themselves on seeing a doctor or by the hospital’s restriction policy. Answers were required to be based on the time period around August 17, 2020.
the overall response rate was 48.9% (651 replies). Among the hospitals that replied, 504 had also replied to the 1st survey (77.4%).

Figure 2 shows the comparison between surveys about hospital acceptance during the COVID-19 pandemic and the presence of a cardiologist on the hospital-level COVID-19 team. Compared with the 1st survey, the percentage of hospitals accepting all patients, regardless of a COVID-19 diagnosis, increased (18.8% to 31.5%) and the number of that declined to accept COVID-19 patients at both the hospital level and the department level decreased (32.7% to 27.3% and 32.5% to 29.2%, respectively).

Of the total of 651 departments, 345 (53.0%) restricted at least 1 of the listed procedures from early March to early August. Among these hospitals, the specific hospital restriction policy changed during that periods (Figure 3).

Furthermore, TEE (61.2%) and catheterizations (55.1%) were restricted most frequently, and these restriction rates peaked between the end of April and early May.

Figure 4 shows the results of a typical cardiovascular disease exacerbation in each department. Heart failure was most frequently experienced (43.8%), followed by ischemic heart disease and hypertension (28.7% and 25.3%, respectively).

**Discussion**

This study was a retrospective descriptive analysis of a 2nd nationwide survey regarding departmental policy during the COVID-19 pandemic. This is the first report describing temporal changes in policy adopted by hospitals and cardiology departments. We confirmed the exacerbation of typical non-COVID-19 cardiovascular diseases under the restrictions. This information should be heeded in upcoming

**Results**

After excluding 27 hospitals without a valid e-mail address, Departmental policy also included any restrictions in the cardiology department on practices in outpatient clinics, emergency rooms, echocardiography for both outpatients and inpatients, transesophageal echocardiography (TEE), catheterizations (coronary, peripheral, and right heart), ablation and electrophysiological study (EPS) therapies, treadmills, cardiopulmonary exercise testing (CPX), scheduled operations, and scheduled hospitalizations. If the cardiology department had restricted any of these practices, the questionnaire asked if/when it was planned to lift these restrictions.

**Data Linkage and Statistics**

A similar survey (1st survey) performed on April 13, 2020 included some of the same questions as the 2nd survey, which was used to illustrate the differences between April and August. The linked questions were: “Does your hospital/department accept COVID-19 patients?” and “Does your hospital have a COVID-19 team, and does that team include a cardiologist?” The restriction rate for each examination and procedure in a month was calculated via the total number of hospitals restricted for each procedure divided by the total number of hospitals in each month. The total number of reported COVID-19 cases was retrieved from Toyo Keizai Online (https://toyokeizai.net/sp/visual/tnko/covid19/, accessed December 7, 2020) and officially reported by the Ministry of Health, Labour, and Welfare in Japan (https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000121431_00086.html, accessed December 7, 2020) (Figure 1).
COVID-19-related pandemic situations.

Comparisons Between Surveys

Our data revealed significant general policy differences between the 1st and 2nd surveys. The acceptance of COVID-19 patients at both the hospital level and the department level increased. Considering the actual reported number of COVID-19 patients in Japan was greater in August than in April, these data imply that departmental policies were not determined solely by the reported number of COVID-19 cases. There are several possible reasons. First, many hospitals lacked adequate personal protective medical equipment, especially in April. Many strategies, including nationwide supply chain improvement, international collaborations, new technological improvements such as 3D printing, and improved allocation of medical resources across the country, were implemented rapidly, which could have ameliorated the shortage of medical resources. Second, there was widespread concern about the infectivity and stigmatization of the disease. Especially in Japan, the first stigmatization of COVID-19 was reported at the end of March 2020. Risks to healthcare providers were also reported, which could have reduced the motivation of healthcare workers. Appropriate and precise knowledge and information about COVID-19 that could have reduced such concerns have spread gradually. In addition, the number of COVID-19 teams that included a cardiologist on the team had also increased. Although the effect of placing a cardiologist on the COVID-19 team has not been fully evaluated, having a heart team during decision making would help to provide appropriate and rapid sharing of information for heart-related decisions.

Sequential Changes in Cardiology Department Policy

Our results also revealed that almost half of the departments had restricted cardiovascular procedures early in 2020 during the COVID-19 pandemic. The restriction rate peaked around the end of April. As discussed above, the same reasons could be applicable to the time period of restriction. Unfortunately, there are few reports on restrictions implemented in cardiology departments in general. Ngamou-Gnindjio et al reported the majority of cardiology services (76.5%) and consulting programs (85%) were reconfigured in Africa around July 2020. This suggests structural changes in cardiology departments occurred more frequently in other countries. Further evaluation of these structural changes and their effect on patient outcomes are necessary.

Indirect Effect of COVID-19 on Other Typical Cardiovascular Care

The effect of the COVID-19 pandemic on cardiovascular disease care has also not been fully evaluated. Among cardiovascular diseases, the striking reduction in admissions for acute myocardial infarction (AMI) has been most frequently reported. De Rosa et al reported a 48.4% reduction in admissions for AMI in Italy. Healthcare delivery systems in northern California also reported a 48% reduction of myocardial infarction admissions. Severino et al revealed heart failure admissions in Italy also reduced (incidence rate ratio: 0.57 [95% confidence interval 0.45–0.72]) from February to March 2020. Despite the subjective nature of our data, many clinical experiences about the deterioration of patient health due to heart failure and ischemic heart disease support our findings. In addition, our data revealed that other typical cardiovascular diseases, such as hypertension and arrhythmia, should not be ignored.

Study Limitations

First, the survey response rate was less than 60%, so sampling bias cannot be denied. Second, the subjective
nature of the exacerbation of typical cardiovascular disease is also noteworthy. We should validate these results by using a nationwide registry and administrative datasets.

Conclusions
Cardiology departmental policies changed during the initial and second wave of COVID-19. Several procedures were restricted due to the COVID-19 pandemic. The exacerbation of typical non-COVID-19 cardiovascular diseases from the perspective of a clinical cardiologist should be considered.

Acknowledgments
We acknowledge every JCS-certified training hospital and all board members of the Japanese Circulation Society for their role in this nationwide survey (https://www.j-circ.or.jp/cms/wp-content/uploads/2021/01/Acknowledgments.pdf, Japanese). We appreciate the special assistance from Taro Inaba, as well as the office staff of the Japanese Circulation Society, in the support of a COVID-19 team of the Japanese Circulation Society.

Sources of Funding
None.

Disclosures
No conflicts of interest exist in this study. But we declare that some of our co-authors, S.S., I.K., and K.N. are in member of Circulation Reports’ Editorial Team.

IRB Information
This study was approved by Japanese Circulation Society Ethics Committee (No.11-1)

References
1. Omer SB, Malani P, del Rio C. The COVID-19 pandemic in the US: A clinical update. JAMA 2020; 323: 1767 – 1768.
2. Mossa-Basha M, Medverd J, Linnau K, Lynch JB, Wener MH, Kicska G, et al. Policies and guidelines for COVID-19 preparedness: Experiences from the University of Washington. Radiology 2020; 296: E26 – E31.
3. Shih CK, Chan JC, Lai JS. Maintenance of ophthalmic specialist out-patient service during the COVID-19 outbreak: The University of Hong Kong experience. Eye (Lond) 2020; 34: 1241 – 1242.
4. Kirkpatrick JN, Mitchell C, Taub C, Kort S, Hung I, Swaminathan M. ASE statement on protection of patients and echocardiography service providers during the 2019 novel coronavirus outbreak: Endorsed by the American College of Cardiology. J Am Coll Cardiol 2020; 75: 3078 – 3084.
5. Mullen B. ACC Clinical Bulletin COVID-19: Clinical guidance for the CV Care Team; 2020. https://www.acc.org/~media/Non-Clinical/Files-PDFs-Excel-MS-Word-etc/2020/02/S20028-ACC-Clinical-Bulletin-Coronavirus.pdf?fbclid=IwAR1ABbqUAoYdoFkr-kKJV9e91yfIN26edOq72daAyrb6qOpkrHtL74MoEw (accessed January 12, 2021).
6. Arakawa T, Kumasaka L, Nakanishi M, Nagayama M, Adachi H, Ikeda K, et al. Regional clinical alliance path and cardiac rehabilitation after hospital discharge for acute myocardial infarction patients in Japan: A nationwide survey. Circ J 2016; 80: 1750 – 1755.
7. Guan D, Wang D, Hallegatte S, Davis SJ, Huo J, Li S, et al. Global supply-chain effects of COVID-19 control measures. Nat Hum Behav 2020; 4: 577 – 587.
8. Ishack S, Lipner SR. Applications of 3D printing technology to address COVID-19-related supply shortages. Am J Med 2020; 133: 771 – 773.
9. Yoshioka T, Maeda Y. COVID-19 stigma induced by local government and media reporting in Japan: It’s time to reconsider risk communication lessons from the Fukushima Daiichi Nuclear Disaster. J Epidemiol 2020; 30: 372 – 373.
10. Taylor S, Landry CA, Racher GS, Paluszek MM, Asmundson GIG. Fear and avoidance of healthcare workers: An important, under-recognized form of stigmatization during the COVID-19 pandemic. J Anxiety Disorder 2020; 75: 102289.
11. Nganou-Gnindjio CN, Temgoua M, Kuate L, Nkoke C, Tochie JN, Ndobo V, et al. Delivery of cardiology services in Africa during the COVID-19 pandemic: What should we expect after this pandemic? 2020; doi:10.21203/rs.3rs-74166/v1.
12. De Rosa S, Spaccarotella C, Basso C, Calabrò MP, Curcio A, Filardi PP, et al. Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era. Eur Heart J 2020; 41: 2083 – 2088.
13. Solomon MD, McNulty EJ, Rana JS, Leong TK, Lee C, Sung SH, et al. The Covid-19 pandemic and the incidence of acute myocardial infarction. Eur J Heart Fail 2020; 22: 1101 – 1108.
14. Severino P, D’Amato A, Saglietto A, D’Ascenzo F, Marinu C, Schiavone M, et al. Reduction in heart failure hospitalization rate during coronavirus disease 19 pandemic outbreak. ESC Heart Fail 2020; 7: 4182 – 4188.